These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 29222272)

  • 1. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.
    Liu WR; Shipp MA
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):310-316. PubMed ID: 29222272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.
    Liu WR; Shipp MA
    Blood; 2017 Nov; 130(21):2265-2270. PubMed ID: 29167175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
    Roemer MG; Advani RH; Ligon AH; Natkunam Y; Redd RA; Homer H; Connelly CF; Sun HH; Daadi SE; Freeman GJ; Armand P; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Rodig SJ; Shipp MA
    J Clin Oncol; 2016 Aug; 34(23):2690-7. PubMed ID: 27069084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.
    Roemer MG; Advani RH; Redd RA; Pinkus GS; Natkunam Y; Ligon AH; Connelly CF; Pak CJ; Carey CD; Daadi SE; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Shipp MA; Rodig SJ
    Cancer Immunol Res; 2016 Nov; 4(11):910-916. PubMed ID: 27737878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass cytometry of Hodgkin lymphoma reveals a CD4
    Cader FZ; Schackmann RCJ; Hu X; Wienand K; Redd R; Chapuy B; Ouyang J; Paul N; Gjini E; Lipschitz M; Armand P; Wu D; Fromm JR; Neuberg D; Liu XS; Rodig SJ; Shipp MA
    Blood; 2018 Aug; 132(8):825-836. PubMed ID: 29880615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
    Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA
    J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complex Immune Evasion Strategies in Classical Hodgkin Lymphoma.
    Wein F; Weniger MA; Höing B; Arnolds J; Hüttmann A; Hansmann ML; Hartmann S; Küppers R
    Cancer Immunol Res; 2017 Dec; 5(12):1122-1132. PubMed ID: 29070649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
    Michot JM; Lazarovici J; Ghez D; Danu A; Fermé C; Bigorgne A; Ribrag V; Marabelle A; Aspeslagh S
    Eur J Cancer; 2017 Nov; 85():67-77. PubMed ID: 28892775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
    Green MR; Monti S; Rodig SJ; Juszczynski P; Currie T; O'Donnell E; Chapuy B; Takeyama K; Neuberg D; Golub TR; Kutok JL; Shipp MA
    Blood; 2010 Oct; 116(17):3268-77. PubMed ID: 20628145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.
    Carey CD; Gusenleitner D; Lipschitz M; Roemer MGM; Stack EC; Gjini E; Hu X; Redd R; Freeman GJ; Neuberg D; Hodi FS; Liu XS; Shipp MA; Rodig SJ
    Blood; 2017 Nov; 130(22):2420-2430. PubMed ID: 28893733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The biology of classical Hodgkin lymphoma.
    Kosydar S; Ansell SM
    Semin Hematol; 2024 Aug; 61(4):212-220. PubMed ID: 38824068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion.
    Wienand K; Chapuy B; Stewart C; Dunford AJ; Wu D; Kim J; Kamburov A; Wood TR; Cader FZ; Ducar MD; Thorner AR; Nag A; Heubeck AT; Buonopane MJ; Redd RA; Bojarczuk K; Lawton LN; Armand P; Rodig SJ; Fromm JR; Getz G; Shipp MA
    Blood Adv; 2019 Dec; 3(23):4065-4080. PubMed ID: 31816062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Microenvironment in classical Hodgkin lymphoma].
    Mottok A
    Pathologe; 2020 May; 41(3):254-260. PubMed ID: 32239325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
    Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
    BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma.
    Solórzano JL; Menéndez V; Parra E; Solis L; Salazar R; García-Cosío M; Climent F; Fernández S; Díaz E; Francisco-Cruz A; Khoury J; Jiang M; Tamegnon A; Montalbán C; Melero I; Wistuba I; De Andrea C; F García J
    Oncoimmunology; 2024; 13(1):2388304. PubMed ID: 39135889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
    Villasboas JC; Ansell S
    Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance.
    Aldinucci D; Celegato M; Casagrande N
    Cancer Lett; 2016 Sep; 380(1):243-52. PubMed ID: 26474544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.
    Green MR; Rodig S; Juszczynski P; Ouyang J; Sinha P; O'Donnell E; Neuberg D; Shipp MA
    Clin Cancer Res; 2012 Mar; 18(6):1611-8. PubMed ID: 22271878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma.
    Kawashima M; Carreras J; Higuchi H; Kotaki R; Hoshina T; Okuyama K; Suzuki N; Kakizaki M; Miyatake Y; Ando K; Nakayama M; Umezu S; Horie R; Higuchi Y; Katagiri K; Goyama S; Kitamura T; Chamoto K; Yano S; Nakamura N; Kotani A
    Leukemia; 2020 Sep; 34(9):2405-2417. PubMed ID: 32089543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab in the Treatment of Hodgkin Lymphoma.
    Ansell SM
    Clin Cancer Res; 2017 Apr; 23(7):1623-1626. PubMed ID: 27881581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.